Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Latest News

Insulet's Q2 2026 Earnings: What to Expect

Barchart • 07/22/2026

1 Healthcare Stock to Target This Week and 2 We Brush Off

StockStory • 07/20/2026

The Worst-Performing S&P 500 Stocks Of 2026 So Far

Money Digest • 07/20/2026

Goldman Flags 3 AI-Resistant Investment Themes to Watch

Barrons.com • 07/20/2026

Top Research Reports for Interactive Brokers, Danaher & S&P Global

Zacks • 07/16/2026